Dibenedetto, S P

Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. [electronic resource] - Blood Aug 1997 - 1226-32 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0006-4971


Adolescent
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Asparaginase--administration & dosage
Biomarkers, Tumor--analysis
Blotting, Southern--methods
Bone Marrow--pathology
Child
Child, Preschool
Cohort Studies
Cyclophosphamide--administration & dosage
Cytarabine--administration & dosage
DNA, Neoplasm--analysis
Daunorubicin--administration & dosage
Disease-Free Survival
Evaluation Studies as Topic
Female
Fluorometry
Gene Rearrangement, delta-Chain T-Cell Antigen Receptor
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
Humans
Immunophenotyping
Infant
Italy--epidemiology
Leucovorin--administration & dosage
Leukemia-Lymphoma, Adult T-Cell--drug therapy
Male
Mercaptopurine--administration & dosage
Methotrexate--administration & dosage
Neoplasm, Residual
Neoplastic Stem Cells--chemistry
Nucleic Acid Hybridization--methods
Polymerase Chain Reaction--methods
Prednisone--administration & dosage
Prognosis
Prospective Studies
Receptors, Antigen, T-Cell, gamma-delta--analysis
Remission Induction
Sensitivity and Specificity
Treatment Outcome
Vincristine--administration & dosage